Partnership integrates Scipher’s PrismRA to deliver insights into therapy response segmentation
Scipher Medicine, a precision immunology company dedicated to transforming patient care through data-driven insights, announced a strategic collaboration with a top 3 global pharmaceutical company. The partnership aims to enhance clinical trials by incorporating PrismRA, Scipher’s proprietary precision medicine diagnostic, into an ongoing trial.
Health Technology Insights: 3Gen Consulting Invests in Encipher Health to Advance AI-Driven Risk Adjustment in U.S. Healthcare
PrismRA is designed to analyze a patient’s molecular profile to predict non-response to certain therapies, enabling a more precise understanding of patient populations. By applying PrismRA within the context of this clinical trial, Scipher Medicine will provide critical insights into therapy response segmentation. These insights are expected to help refine patient selection strategies, better characterize treatment effects across subpopulations, and inform the design of future studies.
This collaboration highlights the growing recognition of the value of precision medicine diagnostics in enhancing the efficiency and effectiveness of the drug development lifecycle. By prospectively or retrospectively analyzing patient data using advanced molecular tools like PrismRA, pharmaceutical companies can gain deeper biological insights that may substantially de-risk and accelerate the path from clinical trial to patient benefit.
Health Technology Insights: Artera Achieves Nationwide Access for its ArteraAI Prostate Test
“We are incredibly pleased to partner with one of the world’s leading pharmaceutical companies to embed precision medicine insights directly into their clinical trial process,” said Reg Seeto, CEO of Scipher Medicine. “This collaboration exemplifies our commitment to driving precision medicine into drug development. By applying our validated diagnostic capabilities like PrismRA, we aim to help our partners better understand therapy response, optimize trial design, and ultimately bring the right therapies to the right patients more efficiently.”
Scipher Medicine leverages a robust suite of capabilities, including its AI-driven target selection and ranking methodologies, therapy response/non-response biomarker and diagnostic development, and its industry-leading clinico-transcriptomic data asset, to drive innovation across the entire therapeutic development spectrum. This partnership is a testament to the increasing adoption of these advanced approaches by leaders in the pharmaceutical industry.
Health Technology Insights: CIVIE Launches RadPod, an AI-Empowered On-Demand Radiology Reading Platform
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
